Projects per year
Personal profile
Education
- 2000 Ph.D., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1996 M.S., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1994 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2023.08- Dean, Research and Development, Taipei Medical University
- 2021- Director, Research Center of Drug Discivery, Taipei Medical University
- 2017- Director, Biomedical Commercialization Center, Taipei Medical University
- 2018-2023 Dean, College of Pharmacy, Taipei Medical University
- 2015-2022 Director, Research Center of Pharmaceutical Sciences and Biotechnology, College of Pharmacy, Taipei Medical University
- 2013-2017 Associate Dean, College of Pharmacy, Taipei Medical University
- 2012-2016 Director, Core Laboratory of Drug Organic Synthesis, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
- 2012- Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2008-2012 Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2004-2008 Assistant Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2000-2004 Postdoctoral Research, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes
Awards
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
Research Interests
- Discovery and Development of small molecular compounds towards IND
- Structure optimization through rational drug design and intelligent modification
- Medicinal Chemistry
Fingerprint
Dive into the research topics where Jing-Ping Liou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Organic Synthesis for Tumor Microenvironment Disruption and Immune Memory T Cell Enhancement
Liou, J.-P. (PI)
8/1/25 → 7/31/26
Project: A - Government Institution › b - National Science and Technology Council
-
114教育部STEM「智慧生技製藥：化學 × 生物 × AI人才培育計畫」
Liou, J.-P. (PI)
8/1/25 → 7/31/26
Project: A - Government Institution › d - Ministry of Education
-
Design and Synthesis of Dual-Target Drugs Inhibiting Canonical and Non-Canonical Mif Receptors to Overcome the Gbm Ecosystem( I )
Liou, J.-P. (PI)
8/1/25 → 7/31/26
Project: A - Government Institution › b - National Science and Technology Council
-
Design, Synthesis and Bio-evaluation of Allopregnanolone derivatives dual Histone Deacetylase Inhibitors as Glioblastoma Multiforme Therapeutic Agents
Liou, J.-P. (PI)
7/1/25 → 2/28/26
Project: A - Government Institution › b - National Science and Technology Council
-
新穎具血腦障壁穿透能力試劑之開發以作為TMZ抗藥性及復發性膠質母細胞瘤用藥
Liou, J.-P. (PI)
1/1/25 → 12/31/25
Project: B - Project of TMU › h - Higher Education Sprout Project
-
Design and development of dual drug-loaded liposomes encapsulating gentamicin and curcumin via microfluidic synthesis: A Box-Behnken experimental approach
Yugatama, A., Chao, F. C., Hsu, M. J., Huang, S. W., Liou, J. P. & Hsieh, C. M., Jan 2026, In: Journal of Drug Delivery Science and Technology. 115, 107750.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Dual suppression of stemness and redox adaptation in glioblastoma through filaggrin upregulation by an abiraterone-based HDAC inhibitor
Tran, H. Y., Sharma, R., Lin, H.-Y., Yeh, T.-Y., Shen, C.-J., Hsu, T.-I. & Liou, J.-P., Dec 2026, In: Journal of Biomedical Science. 33, 1, 38.Research output: Contribution to journal › Article › peer-review
Open Access -
Formulation and administration timing of lipid derivatized JAK-inhibitor and corticosteroid modulate saRNA-LNP inflammation and expression
Bathula, N. V., Casmil, I. C., Friesen, J. J., Yuan, E., Liao, S., Maiti, B., Liou, J. P., Lai, M. J., Li, S. D., Chen, S., Tam, Y. Y. C. & Blakney, A. K., Apr 10 2026, In: Journal of Controlled Release. 392, 114736.Research output: Contribution to journal › Article › peer-review
Open Access -
Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids
Narwanti, I., Yu, Z. Y., Sethy, B., Zheng, P. L., Cheng, L. H., Tsai, K. K., Lee, S. B. & Liou, J. P., Jan 5 2026, In: European Journal of Medicinal Chemistry. 301, 118215.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Citation (Scopus) -
A Dual CYP17A1/HDAC6 Inhibitor for Targeted Prostate Cancer Therapy
Tran, H. Y., Lin, C. L., Lin, H. Y., Shen, C. J., Sharma, R., Liou, J. P. & Hsu, T. I., Oct 2025, In: FASEB Journal. 39, 20, e71152.Research output: Contribution to journal › Article › peer-review
1 Link opens in a new tab Citation (Scopus)
Datasets
-
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
Dataset
-
Additional file 2: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202887.v1, https://springernature.figshare.com/articles/Additional_file_2_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202887/1
Dataset
-
Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202881.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202881/1
Dataset
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Lai, M.-J. (Creator), Lee, C.-H. (Creator), Chao, Y.-H. (Creator), Mehndiratta, S. (Creator), Chen, M.-C. (Creator), Liou, J.-P. (Creator) & Lee, H.-Y. (Creator), Taylor & Francis, 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
Dataset
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M.-W. (Contributor), Chang, L.-H. (Contributor), Tu, H.-J. (Contributor), Chang, C.-D. (Contributor), Lai, M.-J. (Contributor), Chen, Y.-Y. (Creator), Liou, J.-P. (Creator), Teng, C.-M. (Contributor) & Pan, S.-L. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
Dataset